Liver tumor characterization: Comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - A multicenter trial

Journal of Computer Assisted Tomography

Volumn 30, Issue 3, 2006, Pages 345-354

  Halavaara, Juha ^a   Breuer, Josy ^b   Ayuso, Carmen ^b   Balzer, Thomas ^b   Bellin, Marie France ^b   Blomqvist, Lennart ^b   Carter, Rick ^b   Grazioli, Luigi ^b   Hammerstingl, Renate ^b   Huppertz, Alexander ^b   Jung, Gregor ^b   Krause, Denis ^b   Laghi, Andrea ^b   Leen, Edward ^b   Lupatelli, Luciano ^b   Marsili, Luca ^b   Martin, Julio ^b   Pretorius, E Scott ^b   Reinhold, Caroline ^b   Stiskal, Michael ^b   Stolpen, Alan H ^b   more..

^a JORVI HOSPITAL   (Finland)

^b NONE

Author keywords

Contrast agent; Lesion; Liver; Liver CT; Liver magnetic resonance; Magnetic resonance

Indexed keywords

COMPUTERIZED TOMOGRAPHY; MAGNETISM; RESONANCE;

CONTRAST AGENT; LESION; LESION CLASSIFICATION; LIVER COMPUTED TOMOGRAPHY; LIVER LESIONS; LIVER MAGNETIC RESONANCE; LIVER TUMORS; OFF SITES; SPIRAL COMPUTED TOMOGRAPHIES; TUMOR CHARACTERIZATION;

MAGNETIC RESONANCE IMAGING;

CONTRAST MEDIUM; GADOXETIC ACID;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER DIAGNOSIS; CHILL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LIVER CANCER; LIVER CELL; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; SINGLE BLIND PROCEDURE; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STANDARD; TREMOR; TUMOR CLASSIFICATION; VOMITING;

EID: 33745285710     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-200605000-00001     Document Type: Article

References (30)

1. Bramhall SR, Gur U, Coldham C, et al. Liver resection for colorectal metastases. Ann R Coll Surg Engl. 2003;85:334-339.
2. Gazelle GS, Goldberg SH, Solbiati L, et al. Tumor ablation with radiofrequency energy. Radiology. 2000;217:633-646.
3. Forsberg F, Piccoli C, Liu J-B, et al. Hepatic tumor detection: MR imaging and conventional US versus pulse-inversion harmonic US of NC100100 during its reticuloendothelial system-specific phase. Radiology. 2002;222:824-829.
4. Kamel IR, Choti MA, Horton KM, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology. 2003;227:752-757.
5. Mahfouz A-E, Hamm B, Wolf K-J. Peripheral wash-out: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology. 1994;190:49-52.
6. Mitchell DG, Saini S, Weinreb J, et al. Hepatic metastases and cavernous hemangiomas: distinction with standard-and triple-dose gadoteridol-enhanced MR imaging. Radiology. 1994;193:49-57.
7. Numminen K, Halavaara J, Isoniemi H, et al. MR imaging of the liver: true FISP sequence facilitates rapid and reliable distinction between hepatic hemangiomas and liver malignancies. J Comput Assist Tomogr. 2003;27:571-576.
8. Miller WJ, Baron RL, Dodd GD III, et al. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology. 1994;193:645-650.
9. Baron RL, Oliver JH III, Dodd GD III, et al. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced helical CT. Radiology. 1996;199:505-511.
10. Tang Y, Yamashita Y, Namimoto T, et al. Characterization of focal liver lesions with half-fourier acquisition single-shot turbo-spin-echo (HASTE) and inversion recovery (IR)-HASTE sequences. J Magn Reson Imaging. 1998;8:438-445.
11. Ros PR, Lubbers PR, Olmsted WW, et al. Hemangioma of the liver: heterogeneous appearance on T2-weighted images. AJR. 1987;149:1167-1170.
12. Paley MR, Mergo PJ, Torres GM, et al. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR. 2000;175:159-163.
13. Coffin CM, Diche T, Mahfouz A, et al. Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol. 1999;9:444-449.
14. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;19:785-792.
15. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199:177-183.
16. Eliasziw M, Donner A. Application of the McNemar test to non-independent matched pair data. Statist Med. 1991;10:1981-1991.
17. Kang BK, Lim JH, Kim SH, et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology. 2003;226:79-85.
18. Reimer P, Jähnke N, Fiebich M, et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology. 2000;217:152-158.
19. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol. 1997;7:275-280.
20. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med. 1991;22:233-237.
21. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MRI imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275.
22. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200:59-67.
23. Ni Y, Marchal G, Yu J, et al. Experimental liver cancers: Mn-DPDP-enhanced rims in MR-microangiographic-histologic correlation study. Radiology. 1993;188:45-51.
24. King LJ, Burkill GJ, Scurr ED, et al. MnDPDP enhanced magnetic resonance imaging of focal liver lesions. Clin Radiol. 2002;57:1047-1057.
25. Ward J, Chen F, Guthrie JA, et al. Hepatic lesion detection after superparamagnetic iron oxide enhancement: comparison of five T2-weighted sequences at 1.0T by using alternative-free response receiver operating characteristic analysis. Radiology. 2000;214:159-166.
26. Federle M, Chezmar J, Rubin DL, et al. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials. Efficacy of early imaging. J Magn Reson Imaging. 2000;12:689-701.
27. Gehl H-B, Bourne M, Grazioli L, et al. Off-site evaluation of liver lesion detection by Gd-BOPTA-enhanced MR imaging. Eur Radiol. 2001;11:187-192.
28. Mathieu D, Coffin C, Kobeiter H, et al. Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir. J Magn Reson Imaging. 1999;10:193-195.
29. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology. 2000;215:727-736.
30. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol. 2001;3:632-641.